Matches in Wikidata for { <http://www.wikidata.org/entity/Q96603207> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q96603207 description "artículu científicu espublizáu en mayu de 2009" @default.
- Q96603207 description "scientific article published on 01 May 2009" @default.
- Q96603207 description "wetenschappelijk artikel" @default.
- Q96603207 description "наукова стаття, опублікована в травні 2009" @default.
- Q96603207 name "Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer" @default.
- Q96603207 name "Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer" @default.
- Q96603207 type Item @default.
- Q96603207 label "Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer" @default.
- Q96603207 label "Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer" @default.
- Q96603207 prefLabel "Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer" @default.
- Q96603207 prefLabel "Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer" @default.
- Q96603207 P1433 Q96603207-DA2F6B05-765B-40F6-946D-5DF6F5745419 @default.
- Q96603207 P1476 Q96603207-385D55FA-7F01-4DC3-B385-67767BF50267 @default.
- Q96603207 P2093 Q96603207-0B48341C-4646-4751-9377-16F0572EB447 @default.
- Q96603207 P2093 Q96603207-2F0E8668-B18D-4A71-8B9D-F595CA08691A @default.
- Q96603207 P304 Q96603207-06C5BD07-FA83-42EF-875A-E0E12417A802 @default.
- Q96603207 P31 Q96603207-829F0799-A52B-4A7A-8A3C-E8140F3A776C @default.
- Q96603207 P356 Q96603207-B718D954-70FD-41D8-9A14-1F0ADDFFA45E @default.
- Q96603207 P433 Q96603207-80DA0922-6F2E-4092-9782-68DE5EA30AB2 @default.
- Q96603207 P478 Q96603207-8D79B536-CB4B-44E0-BC7E-4CA8D2ECA9C5 @default.
- Q96603207 P577 Q96603207-C592CB60-56A0-4FC1-B3F8-B9EEA186307E @default.
- Q96603207 P698 Q96603207-00A6E7E6-8A47-4720-93FC-1E7C426EB241 @default.
- Q96603207 P921 Q96603207-72093D39-8D27-4DE8-B468-68050FAC2639 @default.
- Q96603207 P921 Q96603207-C0751391-4A23-4D3F-9438-165CC64BE759 @default.
- Q96603207 P356 MDP204 @default.
- Q96603207 P698 32560016 @default.
- Q96603207 P1433 Q326122 @default.
- Q96603207 P1476 "Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer" @default.
- Q96603207 P2093 "H Joensuu" @default.
- Q96603207 P2093 "P Bono" @default.
- Q96603207 P304 "967" @default.
- Q96603207 P31 Q13442814 @default.
- Q96603207 P356 "10.1093/ANNONC/MDP204" @default.
- Q96603207 P433 "5" @default.
- Q96603207 P478 "20" @default.
- Q96603207 P577 "2009-05-01T00:00:00Z" @default.
- Q96603207 P698 "32560016" @default.
- Q96603207 P921 Q413299 @default.
- Q96603207 P921 Q41861 @default.